|Systematic (IUPAC) name|
|Pregnancy cat.||C (US)|
|Legal status||Controlled (S8) (AU) Schedule I (CA) Schedule II (US) Class A(NZ)
Injectable: Class A, Oral: A(UK)
Recreational: Oral, Intravenous, Insufflation, Inhalation, Suppository
|Bioavailability||62.7% oral; 79% nasal; 90.3% smoked; 99% rectally; 100% IV|
|Mol. mass||149.2337 g/mol|
| (what is this?)
Methamphetamine (USAN) //, also known as metamfetamine (INN), N-methylamphetamine, methylamphetamine, and desoxyephedrine, is a psychostimulant of the phenethylamine and amphetamine class of psychoactive drugs.
Methamphetamine occurs in two enantiomers, dextrorotary and levorotary. Dextromethamphetamine is a stronger psychostimulant, but levomethamphetamine has a longer half-life and is CNS-active with weaker (approx. one-tenth) effects on striatal dopamine and shorter psychodynamic effects. At high doses, both enantiomers of methamphetamine can induce stereotypy and psychosis, but levomethamphetamine is less desired by drug abusers because of its weaker pharmacodynamic profile. Although rarely prescribed, dextromethamphetamine hydrochloride is approved by the U.S. Food and Drug Administration (FDA) for the treatment of attention deficit hyperactivity disorder and obesity under the trade name Desoxyn.
Illicitly, methamphetamine may be sold either as pure dextromethamphetamine or in a racemic mixture. Both dextromethamphetamine and racemic methamphetamine are Schedule II controlled substances in the United States, and similarly the production, distribution, sale, and possession of methamphetamine is restricted or illegal in many jurisdictions. Internationally, methamphetamine has been placed in Schedule II of the United Nations Convention on Psychotropic Substances treaty.
Contrary to popular misconception, methamphetamine in both powder and crystal form is a hydrochloride salt. The freebase form of methamphetamine (as well as amphetamine) is an oily liquid. The misconception started with the fact that heroin and cocaine are injected or snorted as salts, but they are smoked in freebase form. See also: crack cocaine.
In low dosages, methamphetamine can increase alertness, concentration, and energy in fatigued individuals. In higher doses, it can induce mania with accompanying euphoria, feelings of self-esteem and increased libido. Methamphetamine has a high potential for abuse and addiction, activating the psychological reward system by triggering a cascading release of dopamine in the brain characterized as Amphetamine/Stimulant psychosis.
Chronic abuse may also lead to post-withdrawal syndrome, a result of methamphetamine-induced neurotoxicity to dopaminergic neurons. Post-withdrawal syndrome can persist beyond the withdrawal period for months, and sometimes up to a year. In addition to psychological harm, physical harm – primarily consisting of cardiovascular damage – may occur with chronic use or acute overdose.
- 1 Medical use
- 2 Effects
- 3 Adverse effects
- 4 Pharmacology
- 5 Illicit production of methamphetamine
- 6 See also
- 7 Notes
- 8 References
- 9 External links
In United States, Methamphetamine has been approved by the Food and Drug Administration (FDA) in treating ADHD and exogenous obesity (obesity originating from factors outside of the patient's control) in both adults and children.
Methamphetamine is sold under the name Desoxyn, trademarked by the Danish pharmaceutical company Lundbeck. As of January 2013, the Desoxyn trademark had been sold to Italian pharmaceutical company Recordati.
As methamphetamine is associated with a high potential for misuse, the drug is regulated under the Controlled Substances Act and is listed under Schedule II in the United States. Methamphetamine hydrochloride dispensed in the United States is required to include the following black box warning:
|“||Methamphetamine has a high potential for abuse and should be tried only in weight reduction programs where alternative therapy has been ineffective. Administration of Methamphetamine for prolonged periods may lead to drug dependence. The drug should be prescribed or dispensed sparingly. Misuse may cause sudden death and serious cardiovascular adverse events.||”|
Methamphetamine's levorotary form is available in many over-the-counter nasal decongestant products.
Physical effects can include anorexia, hyperactivity, dilated pupils, flushed skin, excessive sweating, restlessness, dry mouth and bruxism (leading to "meth mouth"), headache, accelerated heartbeat, slowed heartbeat, irregular heartbeat, rapid breathing, high blood pressure, low blood pressure, high body temperature, diarrhea, constipation, blurred vision, dizziness, twitching, insomnia, numbness, palpitations, tremors, dry and/or itchy skin, acne, pallor, and – with chronic and/or high doses – convulsions, heart attack, stroke, and death.
Psychological effects can include euphoria, anxiety, increased libido, alertness, concentration, increased energy, increased self-esteem, self-confidence, sociability, irritability, aggressiveness, psychosomatic disorders, psychomotor agitation, dermatillomania (compulsive skin picking), hair pulling, delusions of grandiosity, hallucinations, excessive feelings of power and invincibility, repetitive and obsessive behaviors, paranoia, and – with chronic use and/or high doses – amphetamine psychosis.
Withdrawal symptoms of methamphetamine primarily consist of fatigue, depression, and increased appetite. Symptoms may last for days with occasional use and weeks or months with chronic use, with severity dependent on the length of time and the amount of methamphetamine used. Withdrawal symptoms may also include anxiety, irritability, headaches, agitation, restlessness, excessive sleeping, vivid or lucid dreams, deep REM sleep, and suicidal ideation.
Methamphetamine use has a high association with depression and suicide as well as serious heart disease, amphetamine psychosis, anxiety, and violent behaviors. Methamphetamine also has a very high addiction risk.
Unlike cocaine and amphetamine, methamphetamine is directly neurotoxic to midbrain dopamine neurons. Moreover, methamphetamine use is associated with an increased risk of Parkinson's disease due to the fact that uncontrolled dopamine effluxion is neurotoxic. Long-term dopamine upregulation occurring as a result of methamphetamine abuse can also cause neurotoxicity, which is believed to be responsible for causing persisting cognitive deficits, such as memory loss, impaired attention, and decreased executive function. Similar to the neurotoxic effects on the dopamine system, methamphetamine can also result in neurotoxicity to serotonergic neurons.
As a result of methamphetamine-induced neurotoxicity to dopaminergic neurons, chronic use may also lead to post acute withdrawals which persist beyond the withdrawal period for months, and even up to a year. A study performed on female Japanese prison inmates suffering from methamphetamine addiction showed that 49% experienced "flashbacks" afterward and 21% experienced a psychosis resembling schizophrenia which persisted for longer than six months post-methamphetamine use; this amphetamine psychosis could be resistant to traditional treatment. Other studies in Japan show that those who experience methamphetamine-induced psychosis are much more likely to experience psychotic symptoms again if they use methamphetamine. In addition to psychological harm, physical harm – primarily consisting of cardiovascular damage – may occur with chronic use or acute overdose.
As with other amphetamines, tolerance to methamphetamine is not completely understood but is known to be sufficiently complex that it cannot be explained by any single mechanism. The extent of tolerance and the rate at which it develops vary widely between individuals, and even within one person. It is highly dependent on dosage, duration of use, and frequency of administration. Tolerance to the awakening effect of amphetamines does not readily develop, making them suitable for the treatment of narcolepsy.
Short-term tolerance can be caused by depleted levels of neurotransmitters within the synaptic vesicles available for release into the synaptic cleft following subsequent reuse (tachyphylaxis). Short-term tolerance typically lasts until neurotransmitter levels are fully replenished; because of the toxic effects on dopaminergic neurons, this can be greater than 2–3 days. Prolonged overstimulation of dopamine receptors caused by methamphetamine may eventually cause the receptors to downregulate in order to compensate for increased levels of dopamine within the synaptic cleft. To compensate, larger quantities of the drug are needed in order to achieve the same level of effects.
Methamphetamine-induced hyperstimulation of pleasure pathways can lead to anhedonia months after use has been discontinued. Investigation of treatments targeting dopamine signalling such as bupropion, or psychological treatments that raise hedonic tone, such as behavioral activation therapy, have been suggested.
It is shown that taking ascorbic acid prior to using methamphetamine may help reduce acute toxicity to the brain, as rats given the human equivalent of 5–10 grams of ascorbic acid 30 minutes prior to methamphetamine dosage had toxicity mediated, yet this will likely be of little avail in solving the other serious behavioral problems associated with methamphetamine use and addiction that many users experience. Large doses of ascorbic acid also lower urinary pH, reducing methamphetamine's elimination half-life and thus decreasing the duration of its actions.
To combat addiction, doctors are beginning to use other forms of stimulants such as dextroamphetamine, the dextrorotatory (right-handed) isomer of the amphetamine molecule, to break the addiction cycle in a method similar to the use of methadone in the treatment of heroin addicts. There are no publicly available drugs comparable to naloxone, which blocks opiate receptors and is therefore used in treating opiate dependence, for use with methamphetamine problems. However, experiments with some monoamine reuptake inhibitors such as indatraline have been successful in blocking the action of methamphetamine. There are studies indicating that fluoxetine, bupropion and imipramine may reduce craving and improve adherence to treatment. Research has also suggested that modafinil can help addicts quit methamphetamine use, as can Topiramate.
Methamphetamine addiction is one of the most difficult forms of addiction to treat. Bupropion, aripiprazole, and baclofen have been employed to treat post-withdrawal cravings, although the success rate is low. Modafinil is somewhat more successful, but this is a Class IV scheduled drug. Adrafinil is the prodrug of Modafinil, being metabolized by the body to Modafinil in 45–60 minutes, and is not a controlled substance. Ibogaine has been used with success in Europe, where it is a Class I drug and available only for scientific research. Mirtazapine has been reported useful in some small-population studies. Since phentermine, a substituted phenethylamine, is a constitutional isomer of methamphetamine, it has been suggested that it may be effective in treating methamphetamine addiction.[medical citation needed]
Abrupt interruption of chronic methamphetamine use results in the withdrawal syndrome in almost 90% of the cases. The mental depression associated with methamphetamine withdrawal lasts longer and is more severe than that of cocaine withdrawal.
Abuse of methamphetamine can result in a stimulant psychosis which may present with a variety of symptoms (e.g. paranoia, hallucinations, delusions). A Cochrane Collaboration review on treatment for amphetamine, dextroamphetamine, and methamphetamine induced psychosis states that about 5-15% of users fail to recover completely. The same review asserts that, based upon at least one trial, antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis. An amphetamine psychosis may also develop occasionally as a treatment-emergent side effect.
Methamphetamine users and addicts may lose their teeth abnormally quickly, a condition informally known as meth mouth. According to the American Dental Association, meth mouth "is probably caused by a combination of drug-induced psychological and physiological changes resulting in xerostomia (dry mouth), extended periods of poor oral hygiene, frequent consumption of high-calorie, carbonated beverages and bruxism (teeth grinding and clenching)". Some reports have also speculated that the caustic nature of the drug is a contributing factor. Methamphetamine also has the potential to cause excessive cigarette smoking for users already smoking. This combined with the methamphetamine can perpetuate the "meth mouth". Similar, though far less severe, symptoms have been reported in clinical use of regular amphetamine, where effects are not exacerbated by extended periods of poor oral hygiene.
Pregnancy and breastfeeding
Methamphetamine present in a mother's bloodstream passes through the placenta to a fetus, and is also secreted into breast milk. Infants born to methamphetamine-abusing mothers were found to have a significantly smaller gestational age-adjusted head circumference and birth weight measurements. Methamphetamine exposure was also associated with neonatal withdrawal symptoms of agitation, vomiting and tachypnea. This withdrawal syndrome is relatively mild and only requires medical intervention in approximately 4% of cases.
Risk of sexually transmitted disease
Men who use methamphetamine, cocaine, MDMA, and ketamine, are twice as likely to have unprotected sex than those who do not use such drugs, according to British research. Methamphetamine use was found to be related to higher frequencies of unprotected sexual intercourse in both HIV-positive and unknown casual partners, according to American psychologist Perry N. Halkitis, a researcher examining methamphetamine use and sexual risk taking behaviors using data collected from community-based participants, an association more pronounced in HIV-positive participants. These findings suggest that methamphetamine use and engagement in unprotected anal intercourse are co-occurring risk behaviors, behaviors that potentially heighten the risk of HIV transmission among gay and bisexual men.
Methamphetamine use allows users of both sexes to engage in prolonged sexual activity, which may cause genital sores and abrasions. Methamphetamine may also cause sores and abrasions in the mouth via bruxism (teeth clenching and grinding) which can turn typically low-risk sex acts such as oral sex into high-risk sexual activity.
As with the injection of any drug, if a group of users share a common needle, blood-borne diseases, such as HIV or hepatitis, can be transmitted. The level of needle sharing among methamphetamine users is similar to that among other drug injection users.
A member of the family of phenethylamines, methamphetamine is chiral, with two isomers, levorotatory and dextrorotatory. The levorotatory form, called levomethamphetamine, is an over-the-counter drug used in inhalers for nasal decongestion.
Methamphetamine is a potent central nervous system stimulant that affects neurochemical mechanisms responsible for regulating heart rate, body temperature, blood pressure, appetite, attention, mood and emotional responses associated with alertness or alarming conditions. The acute physical effects of the drug closely resemble the physiological and psychological effects of an epinephrine-provoked fight-or-flight response, including increased heart rate and blood pressure, vasoconstriction (constriction of the arterial walls), bronchodilation, and hyperglycemia (increased blood sugar). Users experience an increase in focus, increased mental alertness, and the elimination of fatigue, as well as a decrease in appetite. It is known to produce central effects similar to the other stimulants, but at smaller doses, with fewer peripheral effects. Methamphetamine's fat solubility also allows it to enter the brain faster than other stimulants, where it is more stable against degradation by monoamine oxidase (MAO).
The methyl group is responsible for the potentiation of effects as compared to the related compound amphetamine, rendering the substance more lipid-soluble, enhancing transport across the blood–brain barrier, and more stable against enzymatic degradation by monoamine oxidase (MAO). Methamphetamine causes the norepinephrine, dopamine, and serotonin (5HT) transporters to reverse their direction of flow. This inversion leads to a release of these transmitters from the vesicles to the cytoplasm and from the cytoplasm to the synapse (releasing monoamines in rats with ratios of about NE:DA = 1:2, NE: 5HT = 1:60), causing increased stimulation of post-synaptic receptors. Methamphetamine also indirectly prevents the reuptake of these neurotransmitters, causing them to remain in the synaptic cleft for a prolonged period (inhibiting monoamine reuptake in rats with ratios of about: NE:DA = 1:2.35, NE:5HT = 1:44.5). Methamphetamine also interacts with TAAR1 to trigger phosphorylation of PKA and PKC, ultimately resulting in the internalization of dopamine transporters. The presynaptic cell is less able to effectively remove dopamine from the synapse. The binding of methamphetamine to TAAR1 also activates adenylyl cyclase, which allows for increased intracellular cAMP. Taken together, the binding of methamphetamine to TAAR1 results in a massive efflux of neurogenic monoamines with a sustained synaptic presence.
Methamphetamine is a potent neurotoxin, shown to cause dopaminergic degeneration. High doses of methamphetamine produce losses in several markers of brain dopamine and serotonin neurons. Dopamine and serotonin concentrations, dopamine and 5HT uptake sites, and tyrosine and tryptophan hydroxylase activities are reduced after the administration of methamphetamine. It has been proposed that dopamine plays a role in methamphetamine-induced neurotoxicity, because experiments that reduce dopamine production or block the release of dopamine decrease the toxic effects of methamphetamine administration. When dopamine breaks down, it produces reactive oxygen species such as hydrogen peroxide. It is likely that the approximate twelvefold increase in dopamine levels and subsequent oxidative stress that occurs after taking methamphetamine mediates its neurotoxicity. The lab of David Sulzer and colleagues at Columbia University developed a technique known as "intracellular patch electrochemistry" to measure concentrations of dopamine in the cytosol, and found massive increases following methamphetamine, leading to the "cytosolic dopamine hypothesis" of neurotoxicity, in which dopamine oxidation, particularly close to synaptic vesicles, produce oxidative stress that in turn leads to exacerbation of autophagy that can destroy axons and dendrites.
Recent research published in the Journal of Pharmacology And Experimental Therapeutics (2007) indicates that methamphetamine binds to and activates a G protein-coupled receptor called TAAR1. TAARs are a newly discovered receptor family whose members are activated by a number of amphetamine-like molecules called trace amines, thyronamines, and certain volatile odorants.
It has been demonstrated that a high core temperature is correlated with an increase in the neurotoxic effects of methamphetamine.
Following oral administration, methamphetamine is readily absorbed into the bloodstream, with peak plasma concentrations achieved in approximately 3.13 to 6.3 hours post ingestion. The amphetamine metabolite peaks at 10 to 24 hours. Methamphetamine is also well absorbed following inhalation and following intranasal administration. It is distributed to most parts of the body. Methamphetamine is known to produce central effects similar to the other stimulants, but at smaller doses, with fewer peripheral effects. Methamphetamine's high lipophilicity also allows it to cross the blood brain barrier faster than other stimulants, where it is more stable against degradation by monoamine oxidase (MAO).
Methamphetamine is metabolized in the liver with the main metabolites being amphetamine (active) and 4-hydroxymethamphetamine (pholedrine); other minor metabolites include 4-hydroxyamphetamine, norephedrine, and 4-hydroxynorephedrine. Other drugs metabolized to amphetamine and methamphetamine include benzphetamine, furfenorex, and famprofazone. Selegiline (marketed as Deprenyl, EMSAM, and others) is metabolized into levomethamphetamine which in turn is metabolized into levoamphetamine. Although only the D-Isomer of selegiline will metabolize into active metabolites, both isomers may cause a positive result for methamphetamine and amphetamine on a drug test, in certain cases.
It is excreted by the kidneys, with the rate of excretion into the urine heavily influenced by urinary pH. Between 30-54% of an oral dose is excreted in urine as unchanged methamphetamine and 10-23% as unchanged amphetamine. Following an intravenous dose, 45% is excreted as unchanged parent drug and 7% amphetamine. The half-life of methamphetamine is variable with a mean value of between 9 and 12 hours.
Detection in biological fluids
Methamphetamine and amphetamine are often measured in urine, sweat or saliva as part of a drug detection testing program; in plasma or serum to confirm a diagnosis of poisoning in hospitalized victims; or in whole blood to assist in a forensic investigation of a criminal violation or a case of sudden death. Chiral techniques may be employed to help distinguish the source the drug; that is, whether it was obtained legally via prescription or illicitly, or possibly as a result of formation from a prodrug such as famprofazone or selegiline. Chiral separation is needed to assess the possible contribution of l-methamphetamine (found in the Vicks brand of inhaler, for example) toward a positive test result.
In 2011, researchers at John Jay College of Criminal Justice reported that dietary zinc supplements can mask the presence of methamphetamine and other drugs in urine, and similar claims appear in web forum threads on the topic.
Illicit production of methamphetamine
Methamphetamine is most structurally similar to methcathinone and amphetamine. Synthesis is relatively simple, but entails risk with flammable and corrosive chemicals, particularly the solvents used in extraction and purification. The six major routes of production begin with either phenyl-2-propanone (P2P) or with one of the isomeric compounds pseudoephedrine and ephedrine.
One procedure uses the reductive amination of phenylacetone with methylamine, P2P was usually obtained from phenylacetic acid and acetic anhydride, and phenylacetic acid might arise from benzaldehyde, benzylcyanide, or benzylchloride. Methylamine is crucial to all such methods, and is produced from the model airplane fuel nitromethane, or formaldehyde and ammonium chloride, or methyl iodide with hexamine. This was once the preferred method of production by motorcycle gangs in California, until DEA restrictions on the chemicals made the process difficult. Pseudoephedrine, ephedrine, phenylacetone, and phenylacetic acid are currently DEA list I and acetic anhydride is list II on the DEA list of chemicals subject to regulation and control measures. This method can involve the use of mercuric chloride and leaves behind mercury and lead environmental wastes. The methamphetamine produced by this method is racemic, consisting partly of the less-desired levomethamphetamine isomer.
The alternative Leuckart route also relies on P2P to produce a racemic product, but proceeds via methylformamide in formic acid to an intermediate N-formyl-methamphetamine, which is then decarboxylated with hydrochloric acid.
Illicit methamphetamine is more commonly made by the reduction of ephedrine or pseudoephedrine, which produces the more active d-methamphetamine isomer. The maximum conversion rate for ephedrine and pseudoephedrine is 92%, although typically, illicit methamphetamine laboratories convert at a rate of 50% to 75%. Most methods of illicit production involve protonation of the hydroxyl group on the ephedrine or pseudoephedrine molecule.
Though dating back to the discovery of the drug, the Nagai route did not become popular among illicit manufacturers until ca. 1982, and comprised 20% of production in Michigan in 2002 It involves red phosphorus and hydrogen iodide (also known as hydroiodic acid or iohydroic acid). (The hydrogen iodide is replaced by iodine and water in the "Moscow route") The hydrogen iodide is used to reduce either ephedrine or pseudoephedrine to methamphetamine. On heating the precursor is rapidly iodinated by the hydrogen iodide to form iodoephedrine. The phosphorus assists in the second step, by consuming iodine to form phosphorus triiodide (which decomposes in water to phosphorous acid, regenerating hydrogen iodide). Because hydrogen iodide exists in a chemical equilibrium with iodine and hydrogen, the phosphorus reaction shifts the balance toward hydrogen production when iodine is consumed. In Australia, criminal groups have been known to substitute "red" phosphorus with either hypophosphorous acid or phosphorous acid (the "Hypo route"). This is a hazardous process for amateur chemists because phosphine gas, a side-product from in situ hydrogen iodide production, is extremely toxic to inhale. The reaction can also create toxic, flammable white phosphorus waste. Methamphetamine produced in this way is usually more than 95% pure.
The conceptually similar Emde route involves reduction of ephedrine to chloroephedrine using thionyl chloride (SOCl2), followed by catalytic hydrogenation. The catalysts for this reaction are palladium or platinum. The Rosenmund route also uses hydrogen gas and a palladium catalyst poisoned with barium sulfate (Rosenmund reduction), but uses perchloric acid instead of thionyl chloride.
The Birch reduction, also called the "Nazi method", became popular in the mid-to-late 1990s and comprised the bulk of methamphetamine production in Michigan in 2002. It reacts pseudoephedrine with liquid anhydrous ammonia and an alkali metal such as sodium or lithium. The reaction is allowed to stand until the ammonia evaporates. However, the Birch reduction is dangerous because the alkali metal and ammonia are both extremely reactive, and the temperature of liquid ammonia makes it susceptible to explosive boiling when reactants are added. It has been the most popular method in Midwestern states of the U. S. because of the ready availability of liquid ammonia fertilizer in farming regions.
In recent years, a simplified "Shake 'n Bake" one-pot synthesis has become more popular. The method is suitable for such small batches that pseudoephedrine restrictions are less effective, it uses chemicals that are easier to obtain (though no less dangerous than traditional methods), and it is so easy to carry out that some addicts have made the drug while driving. It involves placing crushed pseudoephedrine tablets into a nonpressurized container containing ammonium nitrate, water, and a hydrophobic solvent such as Coleman fuel or automotive starting fluid, to which lye and lithium (from lithium batteries) is added. Hydrogen chloride gas produced by a reaction of salt with sulfuric acid is then used to recover crystals for purification. The container needs to be "burped" periodically to prevent failure under accumulating pressure, as exposure of the lithium to the air can spark a flash fire. The battery lithium can react with water to shatter a container and potentially start a fire or explosion. This mode of synthesis is particularly notorious for causing burns and overwhelming burn wards.
Production and distribution
Until the early 1990s, methamphetamine for the U.S. market was made mostly in labs run by drug traffickers in Mexico and California. Indiana state police found 1,260 labs in 2003, compared to just 6 in 1995, although this may be partly a result of increased police activity. As of 2007, drug and lab seizure data suggests that approximately 80 percent of the methamphetamine used in the United States originates from larger laboratories operated by Mexican-based syndicates on both sides of the border and that approximately 20 percent comes from small toxic labs (STLs) in the United States.
Mobile and motel-based methamphetamine labs have caught the attention of both the U.S. news media and the police. Such labs can cause explosions and fires and expose the public to hazardous chemicals. Those who manufacture methamphetamine are often harmed by toxic gases. Many police departments have specialized task forces with training to respond to cases of methamphetamine production. The National Drug Threat Assessment 2006, produced by the Department of Justice, found "decreased domestic methamphetamine production in both small and large-scale laboratories", but also that "decreases in domestic methamphetamine production have been offset by increased production in Mexico." The report concluded that "methamphetamine availability is not likely to decline in the near term. "
Methamphetamine labs can give off noxious fumes, such as phosphine gas, methylamine gas, solvent vapors, acetone or chloroform, iodine vapors, white phosphorus, anhydrous ammonia, hydrogen chloride/muriatic acid, hydrogen iodide, lithium and sodium gases, ether, or methamphetamine vapors. If performed by amateurs, manufacturing methamphetamine can be extremely dangerous. If the red phosphorus overheats, because of a lack of ventilation, phosphine gas can be produced. This gas is highly toxic and, if present in large quantities, is likely to explode upon autoignition from diphosphine, which is formed by overheating phosphorus.
In July 2007, Mexican officials at the port of Lázaro Cárdenas seized a ship carrying 19 tons of pseudoephedrine, a raw material needed for methamphetamine. The shipment originated in Hong Kong and passed through the United States at the port of Long Beach prior to its arrival in Mexico.
The Australian Crime Commission's illicit drug data report for 2011–2012 was released in western Sydney, Australia on 20 May 2013 and revealed that the average strength of crystal methamphetamine doubled in most Australian jurisdictions within a 12-month period and the majority of domestic laboratory closures involved small "addict-based" operations.
Impurities and adulterants
In Japan, methamphetamine seizures are usually white crystals of high purity, but contain impurities that vary according to the means of production, and are sometimes adulterated.
Diagnostic impurities are the naphthalenes 1-benzyl-methylnaphthalene and 1,3-dimethyl-2-phenylnaphthalene, arising in the Nagai and Leuckart routes, and cis- or trans- 1,2-dimethyl-3-phenylaziridine, ephedrine, or erythro-3,4-dimethyl- 5-phenyloxazolidine, arising in the Nagai and Emde routes; these are absent in the reductive amination route. Characteristic impurities of the Birch route include N-methyl-1-(1-(1,4-cyclohexadienyl))-2-propanamine. Methamphetamine produced by the Birch route contains phenyl-2-propanone, the precursor for the reductive amination route, as a degradation product. However, specific diagnostic impurities are not very reliable in practice, and it is generally preferable for forensic technicians to evaluate a larger profile of trace compounds.
A common adulterant is dimethyl sulfone, a solvent and cosmetic base without known effect on the nervous system; other adulterants include dimethylamphetamine HCl, ephedrine HCl, sodium thiosulfate, sodium chloride, sodium glutamate, and a mixture of caffeine with sodium benzoate.
In the United States, illicit methamphetamine comes in a variety of forms with prices varying widely over time. Most commonly, it is found as a colorless crystalline solid. Impurities may result in a brownish or tan color. Colorful flavored pills containing methamphetamine and caffeine are known as yaa baa (Thai for "crazy medicine").
An impure form of methamphetamine is sold as a crumbly brown or off-white rock, commonly referred to as "peanut butter crank". It may be diluted or cut with non-psychoactive substances like inositol, isopropylbenzylamine or dimethylsulfone. Another popular method is to combine methamphetamine with other stimulant substances, such as caffeine or cathine, into a pill known as a "Kamikaze", which can be particularly dangerous due to the synergistic effects of multiple stimulants. Reports in 2007 of the appearance of flavored "Strawberry Quik meth" circulated in the media and local law enforcement, but were debunked in 2010 by the DEA, although meth of varying colors has been seized.
Rarely, the impure reaction mixture from the hydrogen iodide/red phosphorus route is used without further modification, usually by injection; it is called "ox blood". "Meth oil" refers to the crude methamphetamine base produced by several synthesis procedures. Ordinarily it is purified by exposure to hydrogen chloride, as a solution or as a bubbled gas, and extraction of the resulting salt occurs by precipitation and/or recrystallization with ether/acetone.
- Amphetamine: History, Society, and Culture
- Breaking Bad - An award winning television series involving the criminal production of methamphetamine
- Faces of Meth
- Methamphetamine in the United States
- Montana Meth Project
- Rolling meth lab
- Yudko, Errol; McPherson, Sandra; Hall, Harold (2008-10-29). Methamphetamine Use: Clinical and Forensic Aspects. 408 (2nd ed.). Boca Raton, FL: CRC Press. ISBN 978-0-8493-7273-5.
The DSM IV has amphetamine defined in two ways: Amphetamine dependence (304.40) and Amphetamine abuse (305.70)
- Schep LJ, Slaughter RJ, Beasley DM (August 2010). "The clinical toxicology of metamfetamine". Clinical Toxicology (Philadelphia, Pa.) 48 (7): 675–94. doi:10.3109/15563650.2010.516752. ISSN 1556-3650. PMID 20849327.
- "Methamphetamine". Drug profiles. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). 16 August 2010. Retrieved 1 September 2011.
- Melega, WP; Cho, AK; Schmitz, D; Kuczenski, R; Segal, DS (1999 Feb). "l-methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived l-methamphetamine". The Journal of pharmacology and experimental therapeutics 288 (2): 752–8. PMID 9918585.
- Kuczenski, R; Segal, DS; Cho, AK; Melega, W (1995 Feb). "Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine". The Journal of neuroscience : the official journal of the Society for Neuroscience 15 (2): 1308–17. PMID 7869099.
- Mendelson, J; Uemura, N; Harris, D; Nath, RP; Fernandez, E; Jacob P, 3rd; Everhart, ET; Jones, RT (2006 Oct). "Human pharmacology of the methamphetamine stereoisomers". Clinical pharmacology and therapeutics 80 (4): 403–20. doi:10.1016/j.clpt.2006.06.013. PMID 17015058.
- Castle, L; Aubert, RE; Verbrugge, RR; Khalid, M; Epstein, RS (May 2007). "Trends in medication treatment for ADHD". Journal of Attention Disorders 10 (4): 335–342. doi:10.1177/1087054707299597. PMID 17449832.
- "List of psychotropic substances under international control" (PDF). International Narcotics Control Board. Retrieved 2010-05-10.
- Mack, Avram H.; Frances, Richard J.; Miller, Sheldon I. (2005). Clinical Textbook of Addictive Disorders, Third Edition. New York: The Guilford Press. p. 207. ISBN 1-59385-174-X.
- B. K. Logan. Methamphetamine – Effects on Human Performance and Behavior. Forensic Science Review, Vol. 14, no. 1/2 (2002), p. 142 Full PDF[dead link]
- Cruickshank, CC.; Dyer, KR. (Jul 2009). "A review of the clinical pharmacology of methamphetamine". Addiction 104 (7): 1085–99. doi:10.1111/j.1360-0443.2009.02564.x. PMID 19426289.
- Darke, S.; Kaye, S.; McKetin, R.; Duflou, J. (May 2008). "Major physical and psychological harms of methamphetamine use". Drug Alcohol Rev 27 (3): 253–62. doi:10.1080/09595230801923702. PMID 18368606.
- "Desoxyn (Methamphetamine Hydrochloride) Drug Information: User Reviews, Side Effects, Drug Interactions and Dosage at". Rxlist.com. Retrieved 2011-01-09.
- "Desoxyn". Lundbeck: Desoxyn. Retrieved 2012-12-18.
- Mitler MM, Hajdukovic R, Erman MK (June 1993). "Treatment of narcolepsy with methamphetamine". Sleep 16 (4): 306–17. PMC 2267865. PMID 8341891.
- Mohler; Townsend (2006-04-01). Advanced Therapy In Hypertension And Vascular Disease. PMPH-USA. p. 469. ISBN 978-1-55009-318-6.
- "Are there any effective treatments for methamphetamine abusers?". The Methamphetamine Problem: Question-and-Answer Guide. Tallahassee: Institute for Intergovernmental Research. 2009. Retrieved 2009-08-13.
- "Physiological Effects of a Methamphetamine Overdose | Montana State University". Montana.edu. Retrieved 2011-01-09.
- "Erowid Methamphetamine Vault: Effects". Erowid.org. Retrieved 2011-01-09.
- Dart, Richard (2004). Medical Toxicology. Lippincott Williams & Wilkins. p. 1074. ISBN 978-0-7817-2845-4.
- "What are the signs that a person may be using methamphetamine?". The Methamphetamine Problem: Question-and-Answer Guide. Tallahassee: Institute for Intergovernmental Research. 2009. Retrieved 2009-08-13.
- "Methamphetamine Effects: Including Long Term". KCI — The Anti-Meth Site. Retrieved 2011-01-09.
- "Methamphetamine medical facts from". Drugs.com. Retrieved 2011-01-09.
- "Methamphetamine | Center for Substance Abuse Research (CESAR)". Cesar.umd.edu. Retrieved 2011-01-09.
- "Amphetamines: Drug Use and Dependence | Merck Manual Professional". Merck.com. Retrieved 2011-01-09.
- McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM (September 2005). "The nature, time course and severity of methamphetamine withdrawal". Addiction 100 (9): 1320–9. doi:10.1111/j.1360-0443.2005.01160.x. PMID 16128721.
- Malenka, Eric J. Nestler, Steven E. Hyman, Robert C. (2009). "15". Molecular neuropharmacology : a foundation for clinical neuroscience (2nd ed.). New York: McGraw-Hill Medical. p. 370. ISBN 9780071481274.
- Thrash, B.; Thiruchelvan, K.; Ahuja, M.; Suppiramaniam, V.; Dhanasekaran, M. (2009). "Methamphetamine-induced neurotoxicity: the road to Parkinson's disease" (PDF). Pharmacol Rep 61 (6): 966–77. PMID 20081231.
- Krasnova, I.N.; Cadet, J.L. (May 2009). "Methamphetamine toxicity and messengers of death". Brain Res Rev 60 (2): 379–407. doi:10.1016/j.+brainresrev.2009.03.002. PMC 2731235. PMID 19328213.
- Barr, AM.; Panenka, WJ.; MacEwan, GW.; Thornton, AE.; Lang, DJ.; Honer, WG.; Lecomte, T. (Sep 2006). "The need for speed: an update on methamphetamine addiction". J Psychiatry Neurosci 31 (5): 301–13. PMC 1557685. PMID 16951733.
- Ghodse, Hamid (2002-08-15). Drugs and Addictive Behaviour: A Guide to Treatment. Cambridge University Press. p. 114. ISBN 978-0-521-00001-7.
- Bennett, B.A.; Hollingsworth, C.K.; Martin, R.S.; Harp, J.J. (January 1998). "Methamphetamine-induced alterations in dopamine transporter function". Brain Research 782 (1–2): 219–27. doi:10.1016/S0006-8993(97)01281-X. PMID 9519266.
- You Know... Methamphetamine. Centre for Addiction and Mental Health.
- Adam M. Leventhal (2008). "Anhedonia and Amotivation in Psychiatric Outpatients with Fully Remitted Stimulant Use Disorder". Am J Addict 17 (3): 218–223. doi:10.1080/10550490802019774. PMC 2650808. PMID 18463999.
- Wagner GC, Carelli RM, Jarvis MF (February 1985). "Pretreatment with ascorbic acid attenuates the neurotoxic effects of methamphetamine in rats". Research Communications in Chemical Pathology and Pharmacology 47 (2): 221–8. PMID 3992009.
- Wagner GC, Carelli RM, Jarvis MF (May 1986). "Ascorbic acid reduces the dopamine depletion induced by methamphetamine and the 1-methyl-4-phenyl pyridinium ion". Neuropharmacology 25 (5): 559–61. doi:10.1016/0028-3908(86)90184-X. PMID 3488515.
- Oyler JM, Cone EJ, Joseph RE, Moolchan ET, Huestis MA (October 2002). "Duration of detectable methamphetamine and amphetamine excretion in urine after controlled oral administration of methamphetamine to humans". Clinical Chemistry 48 (10): 1703–14. PMID 12324487.
- The Ice Age (See Below)
- Rothman RB, Partilla JS, Baumann MH, Dersch CM, Carroll FI, Rice KC (March 2000). "Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse". Synapse 35 (3): 222–7. doi:10.1002/(SICI)1098-2396(20000301)35:3<222::AID-SYN7>3.0.CO;2-K. PMID 10657029.
- Winslow BT, Voorhees KI, Pehl KA (2007). "Methamphetamine abuse". American Family Physician 76 (8): 1169–74. PMID 17990840.
- Grabowski J, Shearer J, Merrill J, Negus SS (September 2004). "Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence". Addictive Behaviors 29 (7): 1439–64. doi:10.1016/j.+addbeh.2004.06.018. PMID 15345275.
- "Sleep medicine 'can help ice addicts quit'". Retrieved 2007-12-02.
- "Medication can help recovering meth addicts stay sober, study finds". Retrieved 2012-06-13.
- AJ Giannini. Drugs of Abuse—Second Edition. Los Angeles, Practice Management Information Company, 1997.
- Shoptaw SJ, Kao U, Ling W (2009). "Treatment for amphetamine psychosis (Review)". Cochrane Database of Systematic Reviews (1).
- Hofmann FG. A handbook on drug and alcohol abuse: the biomedical aspects. 2nd Edition. New York: Oxford University Press, 1983.
- Berman, SM.; Kuczenski, R.; McCracken, JT.; London, ED. (Feb 2009). "Potential adverse effects of amphetamine treatment on brain and behavior: a review". Mol Psychiatry 14 (2): 123–42. doi:10.1038/mp.2008.90. PMC 2670101. PMID 18698321.
- "Methamphetamine Use (Meth Mouth)". American Dental Association. Archived from the original on 2008-06-01. Retrieved 2006-12-16.
- "Meth Mouth | Meth awareness and prevention project of South Dakota". Mappsd.org. Retrieved 2011-11-26.
- Hasan AA, Ciancio S (2004). "Relationship between amphetamine ingestion and gingival enlargement". Pediatric Dentistry 26 (5): 396–400. PMID 15460293.
- Shaner JW (September 2002). "Caries associated with methamphetamine abuse". The Journal of the Michigan Dental Association 84 (9): 42–7. PMID 12271905.
- Chomchai C, Na Manorom N, Watanarungsan P, Yossuck P, Chomchai S (2010-12-08). "Methamphetamine abuse during pregnancy and its health impact on neonates born at Siriraj Hospital, Bangkok, Thailand. | PubMed". Southeast Asian J. Trop. Med. Public Health 35 (1): 228–31. PMID 15272773.
- "Up to 20 per cent of gay men have tried crystal meth". PinkNews. 2006-07-14. Retrieved 2011-01-09.
- Halkitis PN, Pandey Mukherjee P, Palamar JJ (2008). "Longitudinal Modeling of Methamphetamine Use and Sexual Risk Behaviors in Gay and Bisexual Men". AIDS and Behavior 13 (4): 783–791. doi:10.1007/s10461-008-9432-y. PMID 18661225.
- Patrick Moore (2005-06-14). "We Are Not OK". VillageVoice. Retrieved 2011-01-09.
- "Methamphetamine Use and Health | UNSW: The University of New South Wales – Faculty of Medicine" (PDF). Retrieved 2011-01-09.
- "Properties and effects of methamphetamine | Turning Point Alcohol and Drug Centre" (PDF). Retrieved 2011-01-09.
- Rothman, et al. "Amphetamine-Type Central Nervous System Potently than they Release Dopamine and Serotonin. " (2001): Synapse 39, 32-41 (Table V. on page 37)
- Xie Z, Miller GM (2009). "A Receptor Mechanism for Methamphetamine Action in Dopamine Transporter Regulation in Brain". Journal of Pharmacology and Experimental Therapeutics 330 (1): 316–325. doi:10.1124/jpet.109.153775. PMC 2700171. PMID 19364908.
- Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, et al. (2001). "Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor". Molecular Pharmacology 60 (6): 1181–1188. PMID 11723224.
- Itzhak Y, Martin JL, Ali SF (October 2002). "Methamphetamine-induced dopaminergic neurotoxicity in mice: long-lasting sensitization to the locomotor stimulation and desensitization to the rewarding effects of methamphetamine". Progress in Neuro-psychopharmacology & Biological Psychiatry 26 (6): 1177–83. doi:10.1016/S0278-5846(02)00257-9. PMID 12452543.
- Davidson C, Gow AJ, Lee TH, Ellinwood EH (August 2001). "Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment". Brain Research. Brain Research Reviews 36 (1): 1–22. doi:10.1016/S0165-0173(01)00054-6. PMID 11516769.
- Yamamoto BK, Zhu W (October 1998). "The effects of methamphetamine on the production of free radicals and oxidative stress". The Journal of Pharmacology and Experimental Therapeutics 287 (1): 107–14. PMID 9765328.
- Mosharov, E.; Gong, L.; Khanna, B.; Sulzer, D.; Lindau, M. (2003). "Intracellular patch electrochemistry: Regulation of cytosolic catecholamines in chromaffin cells". The Journal of neuroscience : the official journal of the Society for Neuroscience 23 (13): 5835–5845. PMID 12843288.
- Mosharov, E. V.; Larsen, K. E.; Kanter, E.; Phillips, K. A.; Wilson, K.; Schmitz, Y.; Krantz, D. E.; Kobayashi, K.; Edwards, R. H.; Sulzer, D. (2009). "Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons". Neuron 62 (2): 218–229. doi:10.1016/j.neuron.2009.01.033. PMC 2677560. PMID 19409267.
- Larsen, K.; Fon, E.; Hastings, T.; Edwards, R.; Sulzer, D. (2002). "Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis". The Journal of neuroscience : the official journal of the Society for Neuroscience 22 (20): 8951–8960. PMID 12388602.
- Reese EA, Bunzow JR, Arttamangkul S, Sonders MS, Grandy DK (April 2007). "Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine". The Journal of Pharmacology and Experimental Therapeutics 321 (1): 178–86. doi:10.1124/jpet.106.115402. PMID 17218486.
- Grandy DK (December 2007). "Trace amine-associated receptor 1-Family archetype or iconoclast?". Pharmacology & Therapeutics 116 (3): 355–90. doi:10.1016/j.pharmthera.2007.06.007. PMC 2767338. PMID 17888514.
- Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL, Durkin MM, Lakhlani PP, Bonini JA, Pathirana S, Boyle N, Pu X, Kouranova E, Lichtblau H, Ochoa FY, Branchek TA, Gerald C (2001). "Trace amines: identification of a family of mammalian G protein-coupled receptors". Proc. Natl. Acad. Sci. U.S.A. 98 (16): 8966–71. doi:10.1073/pnas.151105198. PMC 55357. PMID 11459929.
- Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, Darland T, Suchland KL, Pasumamula S, Kennedy JL, Olson SB, Magenis RE, Amara SG, Grandy DK (2001). "Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor". Mol. Pharmacol. 60 (6): 1181–8. PMID 11723224.
- Scanlan TS, Suchland KL, Hart ME, Chiellini G, Huang Y, Kruzich PJ, Frascarelli S, Crossley DA, Bunzow JR, Ronca-Testoni S, Lin ET, Hatton D, Zucchi R, Grandy DK (2004). "3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone". Nat. Med. 10 (6): 638–42. doi:10.1038/nm1051. PMID 15146179.
- Liberles SD, Buck LB (2006). "A second class of chemosensory receptors in the olfactory epithelium". Nature 442 (7103): 645–50. doi:10.1038/nature05066. PMID 16878137.
- Yuan J, Hatzidimitriou G, Suthar P, Mueller M, McCann U, Ricaurte G (March 2006). "Relationship between temperature, dopaminergic neurotoxicity, and plasma drug concentrations in methamphetamine-treated squirrel monkeys". The Journal of Pharmacology and Experimental Therapeutics 316 (3): 1210–8. doi:10.1124/jpet.105.096503. PMID 16293712.
- Schepers RJ, Oyler JM, Joseph RE, Cone EJ, Moolchan ET, Huestis MA (January 2003). "Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers". Clinical Chemistry 49 (1): 121–32. doi:10.1373/49.1.121. PMID 12507968.
- Hendrickson H, Laurenzana E, Owens SM (2006). "Quantitative determination of total methamphetamine and active metabolites in rat tissue by liquid chromatography with tandem mass spectrometric detection". The AAPS Journal 8 (4): E709–17. doi:10.1208/aapsj080480. PMC 2751367. PMID 17233534.
- Marsel J, Döring G, Remberg G, Spiteller G (1972). "Methamphetamine--a metabolite of the anorectics Benzphetamine and Furfenorex". Zeitschrift für Rechtsmedizin. Journal of legal medicine 70 (4): 245–50. doi:10.1007/BF02079690. PMID 5084766.
- Greenhill B, Valtier S, Cody JT (2003). "Metabolic profile of amphetamine and methamphetamine following administration of the drug famprofazone". Journal of analytical toxicology 27 (7): 479–84. doi:10.1093/jat/27.7.479. PMID 14607003.
- "Drugs and Human Performance FACT SHEETS – Methamphetamine (and amphetamine) | National Highway Traffic Safety Administration (NHTSA)". Nhtsa.gov. Retrieved 2011-01-09.
- National Highway Traffic Safety Administration (NHTSA) - Methamphetamine (And Amphetamine)[dead link]
- de la Torre R, Farré M, Navarro M, Pacifici R, Zuccaro P, Pichini S. Clinical pharmacokinetics of amphetamine and related substances: monitoring in conventional and non-conventional matrices. Clin. Pharmacokinet. 43: 157-185, 2004.
- Paul BD, Jemionek J, Lesser D, Jacobs A, Searles DA. Enantiomeric separation and quantitation of (+/-)-amphetamine, (+/-)-methamphetamine, (+/-)-MDA, (+/-)-MDMA, and (+/-)-MDEA in urine specimens by GC-EI-MS after derivatization with (R)-(-)- or (S)-(+)-alpha-methoxy-alpha-(trifluoromethy)phenylacetyl chloride (MTPA). J. Anal. Toxicol. 28: 449-455, 2004.
- R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 9th edition, Biomedical Publications, Seal Beach, CA, 2011, pp. 1027-1030.
- Venkatratnam, Abhishek; Nathan H. Lents (July 2011). "Zinc Reduces the Detection of Cocaine, Methamphetamine, and THC by ELISA Urine Testing". Journal of Analytical Toxicology 35 (6): 333–340. doi:10.1093/anatox/35.6.333. PMID 21740689.
- B. Remburg and A. H. Stead (1999). "Drug characterization/impurity profiling, with special focus on methamphetamine: recent work of the United Nations International Drug Control Programme" 51 (1-2). Bulletin on Narcotics (UNODC).
- Otto Snow (2002). Amphetamine syntheses. Thoth Press. ISBN 0-9663128-3-X. p. 90.
- "A Synthesis of Amphetamine. J. Chem. Educ. 51, 671 (1974)". Erowid.org. Retrieved 2011-01-09.
- Y. Makino (2005). Investigation of the origin of ephedrine and methamphetamine by stable isotope ratio mass spectrometry: a Japanese experience 52 (1–2). Bulletin on Narcotics.
- Uncle Fester. Secrets of methamphetamine manufacture (8 ed.). Festering Publications.
- Owen, Frank (2007). "Chapter 1: The Rise of Nazi Dope". No Speed Limit: The Highs and Lows of Meth. Macmillan. pp. 17–18. ISBN 978-0-312-35616-3.
- "Types of Meth Labs". METH Awareness and Prevention Project of South Dakota.
- National Drug Intelligence Center. "Methamphetamine". U. S. Department of Justice.
- "The War on Drugs: Methamphetamine, Public Health, and Crime | University of California, Santa Cruz (UCSC)" (PDF). Retrieved 2011-01-09.
- United Nations Office on Drugs and Crime. Laboratory and Scientific Section (2006-03-01). "nagai+route" Recommended methods for the identification and analysis of amphetamine, methamphetamine and their ring-substituted analogues in seized materials. ISBN 9789211482089.
- Michigan Department of Community Health Under a Cooperative Agreement with Agency for Toxic Substances and Disease Registry (2004-11). "Potential Health Effects at a Clandestine Methamphetamine Laboratory using the Red Phosphorus Production Method".
- Hiroyuki Inoue et al. (2008). "http://jhs.pharm.or.jp/data/54%286%29/54_615.pdf". Journal of Health Science 54 (6): 615–622.
- T. S. Cantrell et al. (October 1988). "A study of impurities found in methamphetamine synthesized from ephedrine" 39 (1). Forensic Science International. pp. 39–53. (online version, 2005, at )
- PACIA.org.au[dead link]
- "A single step process for methamphetamine manufacture using hypophosphorus acid". Journal of the Clandestine Laboratory Investigating Chemists Association 5: 14–15. 1995. (cited in Inoue)
- Dominique Albouy et al. (1997-02-15). "Regenerative role of the red phosphorus in the couple 'HIaq/Pred'". Journal of Organometallic Chemistry (Journal of Organometallic Chemistry) 529 (1–2): 295–299. doi:10.1016/S0022-328X(96)06558-8. (archived online 2005 at )
- "Skinner, H. F. (1990). "Methamphetamine Synthesis via HI/Red Phosphorus Reduction of Ephedrine". Forensic Science International 48 (2): 128–134. doi:10.1016/0379-0738(90)90104-7. Reprinted at http://www.rhodium.ws/chemistry/meth.hi-rp.html (dead link)" (cited in )
- Andrew Allen and Thomas S. Cantrell (1989). "Synthetic Reductions in Clandestine Amphetamine and Methamphetamine Laboratories". Forensic Science International 42 (3): 183–199. doi:10.1016/0379-0738(89)90086-8.
- "Recommended methods of the identification and analysis of amphetamine, methamphetamine, and their ring-substituted analogues in seized materials". UNODC. 2006.
- "Illinois Attorney General | Basic Understanding Of Meth". Illinoisattorneygeneral.gov. Retrieved 2011-01-09.
- "New 'shake-and-bake' method for making crystal meth gets around drug laws but is no less dangerous". New York Daily News. Associated Press. August 25, 2009.
- Evan Ziegelman (2011-02-03). "Meth Lab Busted on Warpath". The Columbus Packet.
- "Law Enforcement Facts". U.S.: Indiana State Government. 2007. Archived from the original on 2007-09-22.
- DEA Congressional Testimony, "Drug Threats And Enforcement Challenges". U. S. Drug Enforcement Administration. March 22, 2007. Retrieved 2008-05-03.
- Tiffany Craig. "Meth Explosion Caught On Tape". YouTube (WKRGNews).
- "Methamphetamine – National Drug Threat Assessment 2006". National Drug Intelligence Center. January 2006. Retrieved 2009-08-25.
- Mexico says pseudoephedrine case signals breakdown in port security in U.S., China[dead link] AP, The Telegram (The Canadian Press), July 26, 2007. Olga R. Rodriguez
- MARK SCHLIEBS (20 May 2013). "Purity on the rise as ice tops the drugs wave". The Australian. Retrieved 20 May 2013.
- "The Price and Purity of Illicit Drugs: 1981 Through the Second Quarter of 2003". WhiteHouseDrugPolicy.gov. November 2004. Archived from the original on 2005-10-27.
- Amos, Glenda (September 2007). "The Ice Epidemic". WCTU.com.au. Australia: Woman's Christian Temperance Union. Archived from the original on 2008-07-19. Retrieved 2010-11-17.
- De Vries, Lloyd (May 2, 2007). "Candy Flavored Meth Targets New Users". CBS News. Retrieved 2012-08-09.
- Mikkelson, Barbara. "Strawberry Meth". Snopes.com. Retrieved 2009-08-25.
|Wikimedia Commons has media related to Methamphetamine.|
- NLM Hazardous Substances Data Bank—Entry for d-methamphetamine
- EMCDDA drugs profiles: Methamphetamine (2007)
- EMCDDA paper on Methamphetamine supply in Europe (2009)
- A Key to Methamphetamine-Related Literature—A comprehensive thematic index of methamphetamine research published in academic and scientific journals with links from citations to the PubMed abstracts.
- Poison Information Monograph (PIM 334: Methamphetamine)
- Chronic Amphetamine Use and Abuse—A thorough review on the effects of chronic use (American College of Neuropsychopharmacology)
- ChemSub Online: Methamphetamine
- The Ice Age by ABC Australia—Australian methamphetamine use.
- The Meth Epidemic—Frontline episode
- The World's Most Dangerous Drug—National Geographic.
- The City Addicted to Crystal Meth—BBC (Louis Theroux)
- Childhelp Crystal Darkness
- American Meth
- the fifth estate: Dark Crystal by CBC
- Academic sources
- KLEE (1997). Amphetamine Misuse: International Perspectives on Current Trends. Taylor & Francis. ISBN 9789057020797.